相似文献
1
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy.
Br J Clin Pharmacol. 1979 Aug;8(2):115-24. doi: 10.1111/j.1365-2125.1979.tb05809.x.
2
The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.
Br J Clin Pharmacol. 1979 Aug;8(2):135-42. doi: 10.1111/j.1365-2125.1979.tb05811.x.
3
Effects of digoxin-specific antibodies on accumulation and binding of digoxin by human erythrocytes.
J Clin Invest. 1973 Aug;52(8):1820-33. doi: 10.1172/JCI107364.
4
Inhibition of peripheral blood mononuclear cell proliferation by cardiac glycosides.
Ann Allergy Asthma Immunol. 1997 May;78(5):466-72. doi: 10.1016/S1081-1206(10)63233-4.
5
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation.
Br J Clin Pharmacol. 1979 Aug;8(2):125-34. doi: 10.1111/j.1365-2125.1979.tb05810.x.
6
Interaction of bilirubin with human erythrocyte membranes.
Biochem J. 1983 Feb 15;210(2):489-96. doi: 10.1042/bj2100489.
7
8
Immunological reversal of the effects of digoxin.
Fed Proc. 1977 Aug;36(9):2235-41.
9
Revisiting the binding kinetics and inhibitory potency of cardiac glycosides on Na,K-ATPase (α1β1): Methodological considerations.
J Pharmacol Toxicol Methods. 2018 Nov-Dec;94(Pt 2):64-72. doi: 10.1016/j.vascn.2018.09.001. Epub 2018 Sep 20.
10
Evidence that the uptake of tri-iodo-L-thyronine by human erythrocytes is carrier-mediated but not energy-dependent.
Biochem J. 1982 Oct 15;208(1):27-34. doi: 10.1042/bj2080027.
引用本文的文献
1
Cardiac glycoside-mediated turnover of Na, K-ATPases as a rational approach to reducing cell surface levels of the cellular prion protein.
PLoS One. 2022 Jul 1;17(7):e0270915. doi: 10.1371/journal.pone.0270915. eCollection 2022.
2
The characteristics of [3H]-ouabain binding to human lymphocytes.
Br J Clin Pharmacol. 1983 Jun;15(6):657-65. doi: 10.1111/j.1365-2125.1983.tb01546.x.
3
Influence of digitalis and diuretics on ouabain binding sites on human erythrocytes.
Klin Wochenschr. 1984 Jan 16;62(2):87-92. doi: 10.1007/BF01769668.
4
Measurement of specific [3H]-ouabain binding to different types of human leucocytes.
Br J Clin Pharmacol. 1984 Aug;18(2):153-61. doi: 10.1111/j.1365-2125.1984.tb02447.x.
5
Erythrocytic cation transport receptor numbers and activity in pregnancies complicated by essential hypertension and pre-eclampsia.
Br Med J (Clin Res Ed). 1984 May 5;288(6427):1332-4. doi: 10.1136/bmj.288.6427.1332.
6
Erythrocyte Na+, K+-ATPase and serum digoxin concentrations.
Eur J Clin Pharmacol. 1983;24(6):807-12. doi: 10.1007/BF00607092.
7
Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy.
Klin Wochenschr. 1981 Dec 15;59(24):1323-32. doi: 10.1007/BF01720552.
8
Lack of effect of phenytoin on functions related to Na+,K+-ATPase activity of the intact erythrocytes of epileptic patients.
Br J Clin Pharmacol. 1981 Jul;12(1):79-81. doi: 10.1111/j.1365-2125.1981.tb01858.x.
9
Ouabain inhibition of the sodium-potassium pump: estimation of ED50 in different types of human leucocytes in vitro.
Br J Clin Pharmacol. 1990 Jan;29(1):93-100. doi: 10.1111/j.1365-2125.1990.tb03607.x.
10
The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.
Br J Clin Pharmacol. 1979 Aug;8(2):135-42. doi: 10.1111/j.1365-2125.1979.tb05811.x.
本文引用的文献
1
[Cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane].
Helv Physiol Pharmacol Acta. 1953;11(4):346-54.
2
Effects of digoxin-specific antibodies on accumulation and binding of digoxin by human erythrocytes.
J Clin Invest. 1973 Aug;52(8):1820-33. doi: 10.1172/JCI107364.
3
The effects of sodium and potassium on ouabain binding by human erythrocytes.
J Gen Physiol. 1972 Nov;60(5):609-29. doi: 10.1085/jgp.60.5.609.
4
Binding of the cardiac glycoside ouabain to intact cells.
J Physiol. 1972 Jul;224(2):441-62. doi: 10.1113/jphysiol.1972.sp009904.
5
Binding of tritiated digoxin to human red cell ghosts.
Nature. 1969 Feb 22;221(5182):776. doi: 10.1038/221776a0.
6
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108. doi: 10.1016/0006-2952(73)90196-2.
7
Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.
Br J Clin Pharmacol. 1977 Apr;4(2):223-7. doi: 10.1111/j.1365-2125.1977.tb00698.x.
8
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.
Br J Clin Pharmacol. 1977 Apr;4(2):213-21. doi: 10.1111/j.1365-2125.1977.tb00697.x.
9
The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.
Br J Clin Pharmacol. 1979 Aug;8(2):135-42. doi: 10.1111/j.1365-2125.1979.tb05811.x.
10
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation.
Br J Clin Pharmacol. 1979 Aug;8(2):125-34. doi: 10.1111/j.1365-2125.1979.tb05810.x.
Zotero 插件